Inicio・Lista de Acciones・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Cerrado

SectorSanidad

66.04 -0.18

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

65.18

Máximo

66.82

Métricas clave
By Trading Economics
Ingresos	3M -102M
BPA	-1.17
Empleados	358
EBITDA	-7.6M -112M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+14.73% upside

Dividendos
By Acuity
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	836M 6.4B
Apertura anterior	66.22
Cierre anterior	66.04

Noticias sobre sentimiento de mercado

By Acuity

50%

145 / 340 Clasificación en Healthcare

Xenon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 jul 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

14.73% repunte

Estimación a 12 Meses

Media 75.77 USD 14.73%

Máximo 86 USD

Mínimo 63 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.